Lumen Integrates with Connect IQ to Provide Garmin Users Metabolic Data to Improve Their Performance and Health
11.11.2020 13:00:00 EET | Business Wire | Press release
Lumen, the world’s first hand-held metabolic tracking device, together with Garmin® International, Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), have launched a Connect IQ Lumen App and Garmin Health API integration, allowing users to better understand the impact of fitness and nutrition decisions on their body in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201111005049/en/
Lumen and Garmin integration (Photo: Lumen)
Through the CO2 concentration in a single breath, Lumen measures your metabolic health and provides daily personalised nutrition plans and insights into what your body is burning - fats or carbs. Lumen supports fat burn and improves your metabolic flexibility, which is your body's ability to efficiently switch between using carbs and fats as a fuel source.
Garmin activity trackers and smartwatches help you track and share your activities. Thanks to Lumen data and the Garmin Health API integration, Garmin users can now seamlessly integrate their health and activity data such as heart rate, sleep, steps and calories burned, into the Lumen app and instantly optimise their fitness journey.
“We are thrilled to work with Garmin on this crucial integration. We know how important it is for our users to get valuable insights into their fitness and this will allow them to make more informed decisions about their nutrition and improve their metabolic health,” said Lumen CEO, Daniel Tal.
By combining Garmin and Lumen data, users will be able to monitor their carb fuel consumption through notifications that guide them on when to breathe into Lumen and unlock their day or take a post workout breath. Users can now see how their workout affects their metabolism through recovery macros and a comprehensive Garmin workout summary.
“Lumen is an innovative organisation pushing the boundaries on metabolic health and performance optimisation. Garmin’s Connect IQ platform will enable users to act in real-time to make the right fitness and nutrition decisions at every moment,” said Sean McNamara, Garmin Health Senior Manager Sales and Marketing.
For continual metabolic tracking, Garmin users with compatible devices will also have access to crucial Lumen data such as morning insights, daily and weekly Lumen levels and the Lumen Flex Score which indicates the degree of metabolic flexibility. The goal is to make sure that nutrition and metabolic health remain top of mind.
About Garmin Health
Engineered on the inside for life on the outside, Garmin products have revolutionised the wellness industry. Garmin Health provides enterprise solutions that leverage Garmin wearables and the high-quality sensor data they produce for applications in the corporate wellness, population health, and patient monitoring markets. For more information, visit garmin.com/health, contact the Media Relations department at 913-397-8200, or follow us at facebook.com/garmin, twitter.com/garminnews, instagram.com/garminwellness or youtube.com/garmin.
About Garmin Connect IQ
Connect IQ is the app system for Garmin wearables, bike computers, and outdoor handhelds. Connect IQ allows developers to create on-device solutions for Garmin users. Developers use the Connect IQ SDK to develop apps, and then upload their creations to the Connect IQ store. From there, millions of Garmin users can browse thousands of apps including Starbucks, Spotify, and Amazon Music for download to their Connect IQ compatible device.
About Lumen
Lumen is a device and app that measures your metabolism in a single breath through a complex algorithm and provides daily personalised nutrition based on your metabolic data. At Lumen, we believe that a healthy metabolism is the key to better health, and that everyone can attain it with a little help from Lumen.
Founded in 2014 by scientists and experienced entrepreneurs, Lumen is the biggest metabolic measurement platform in the world, with over 1,000,000 measurements per month. Lumen’s vision is to improve the world's metabolic health and quality of life by empowering individuals to make smarter decisions about their nutrition and lifestyle. Our technology provides individuals with new metrics on metabolism and a system to keep them accountable so they can achieve their health and wellness goals and prevent long-term chronic illness by improving their metabolic health.
Follow us at twitter.com/LumenMetabolism, facebook.com/Lumen.me/, instagram.com/lumen.me/, youtube.com/c/Lumendotme
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005049/en/
Contact information
Press
press@lumen.me
+972548161939
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release
At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 15:57:00 EEST | Press release
MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity, technology, infrastructure, execution, market access and tailored client solutions within an integrated financial ecosystem. The second award acknowledg
Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release
Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom